CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer’s disease model
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Chemokines are important modulators of neuroinflammation and neurodegeneration. In the brains of Alzheimer's disease (AD) patients and in AD animal models, the chemokine CXCL10 is found in high concentrations, suggesting a pathogenic role for this chemokine and its receptor, CXCR3. Recent studies aimed at addressing the role of CXCR3 in neurological diseases indicate potent, but diverse, functions for CXCR3. Here, we examined the impact of CXCR3 in the amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model of AD. We found that, compared with control APP/PSI animals, plaque burden and Aβ levels were strongly reduced in CXCR3-deficient APP/PS1 mice. Analysis of microglial phagocytosis in vitro and in vivo demonstrated that CXCR3 deficiency increased the microglial uptake of Aβ. Application of a CXCR3 antagonist increased microglial Aβ phagocytosis, which was associated with reduced TNF-α secretion. Moreover, in CXCR3-deficient APP/PS1 mice, microglia exhibited morphological activation and reduced plaque association, and brain tissue from APP/PS1 animals lacking CXCR3 had reduced concentrations of proinflammatory cytokines compared with controls. Further, loss of CXCR3 attenuated the behavioral deficits observed in APP/PS1 mice. Together, our data indicate that CXCR3 signaling mediates development of AD-like pathology in APP/PS1 mice and suggest that CXCR3 has potential as a therapeutic target for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Self-citationThe many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523
Microglia as a source and target of cytokines
Hanisch, U. (2002) · Glia · doi:10.1002/glia.10161 · Cited by 1,645
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Inflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355
Astrocytes are active players in cerebral innate immunity
Farina, C., Aloisi, F., & Meinl, E. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.01.005 · Cited by 1,304
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 2×
“A growing number of studies have suggested that Aβ deposition in AD and AD-like models is modulated by the function and activation state of microglia and astrocytes (13, 14, 29, 56, 57).”
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Cole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2009 · Cited by 870
Cited by
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Self-citationThe contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
Minter, M. R., Taylor, J. M., & Crack, P. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13411 · Cited by 451
Ronaldson, P. T., & Davis, T. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20951995 · Cited by 392
Luo, R., Su, L.-Y., Li, G., Yang, J., Liu, Q., Yang, L.-X., Zhang, D.-F., Zhou, H., Xu, M., Fan, Y., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1596488 · Cited by 364
Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis
Bagyinszky, E., Giau, V. V., Shim, K., Suk, K., An, S. S. A., & Kim, S. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.03.031 · Cited by 262
Ceyzériat, K., Ben Haim, L., Denizot, A., Pommier, D., Matos, M., Guillemaud, O., Palomares, M.-A., Abjean, L., Petit, F., Gipchtein, P., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0606-1 · Cited by 256
Jorfi, M., Park, J., Hall, C. K., Lin, C.-C. J., Chen, M., von Maydell, D., Kruskop, J. M., Kang, B., Choi, Y., Prokopenko, D., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01415-3 · Cited by 214
Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Domingues, C., da Cruz e Silva, O. A. B., & Henriques, A. G. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170317113606 · Cited by 203
Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration
Sanchez-Mejias, E., Navarro, V., Jimenez, S., Sanchez-Mico, M., Sanchez-Varo, R., Nuñez-Diaz, C., Trujillo-Estrada, L., Davila, J. C., Vizuete, M., Gutierrez, A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1630-5 · Cited by 175
“In addition, microglia is involved in Abeta phagocytosis [27, 64, 65], senile plaque compaction, and limitation of Abeta toxicity [7, 66].”
BackgroundDá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166
Evolution of neuroinflammation across the lifespan of individuals with Down syndrome
Flores-Aguilar, L., Iulita, M. F., Kovecses, O., Torres, M. D., Levi, S. M., Zhang, Y., Askenazi, M., Wisniewski, T., Busciglio, J., & Cuello, A. C. (2020) · Brain · doi:10.1093/brain/awaa326 · Cited by 138
Maezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., et al. (2018) · Brain · doi:10.1093/brain/awx346 · Cited by 125
“Our result is consistent with several reports showing that selective modulation of specific microglial signalling pathways alters amyloid-b deposition and clearance (El Khoury et al., 2007; Cameron et al., 2012; Heneka et al., 2013; Guillot-Sestier et al., 2015; Hellwig et al., 2015; Johansson et al., 2015; Krauthause…”
BackgroundResultGuedes, J. R., Lao, T., Cardoso, A. L., & El Khoury, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00549 · Cited by 115
Role of Chemokines in the Development and Progression of Alzheimer’s Disease
Wojcieszak, J., Kuczyńska, K., & Zawilska, J. B. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02047-1 · Cited by 97
“2018) and APP/PS1 model of amyloidosis (Krauthausen et al. 2015).”
BackgroundYan, P., Kim, K.-W., Xiao, Q., Ma, X., Czerniewski, L. R., Liu, H., Rawnsley, D. R., Yan, Y., Randolph, G. J., Epelman, S., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152565 · Cited by 95
“GFP-expressing cells were observed adjacent to amyloid plaques (stained with X-34) in all aged APP/PS1 mice (>10 months of age; Figure 3B and Supplemental Table 1), but they were not detected in WT brain parenchyma (Figure 3A) or in 6-month old APP/PS1 mice (Supplemental Table 1) at a stage prior to developmicroglia w…”
Welch, G. M., Boix, C. A., Schmauch, E., Davila-Velderrain, J., Victor, M. B., Dileep, V., Bozzelli, P. L., Su, Q., Cheng, J. D., Lee, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo4662 · Cited by 84
“Another study demonstrates that deficiency of the CXCL10 receptor CXCR3 reduces amyloid deposition and behavioral deficits (62).”
BackgroundRevisiting rodent models: Octodon degus as Alzheimer’s disease model?
Steffen, J., Krohn, M., Paarmann, K., Schwitlick, C., Brüning, T., Marreiros, R., Müller-Schiffmann, A., Korth, C., Braun, K., & Pahnke, J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0363-y · Cited by 62
“APP/PS1 5 26,200 49,400 [58]”
Genetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
Preininger, M. K., Zaytseva, D., Lin, J. M., & Kaufer, D. (2023) · Aging Cell · doi:10.1111/acel.13747 · Cited by 36
Metadata
- Authors
- Krauthausen, M., Kummer, M. P., Zimmermann, J., Reyes-Irisarri, E., Terwel, D., Bulic, B., Heneka, M. T., & Müller, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-12-15
- Volume
- 125
- Issue
- 1
- Pages
- 365-378
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2169708427
- Cited by
- 147
- References
- 32
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.